Method for predicting anti-cancer efficacy of compound targeting apoptosis pathway and composition
A biomarker, cancer technology, applied in the field of cancer treatment
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 1
[0476] This example shows the correlation between Noxa expression and compound efficacy of compound A15 in gastric cancer PDX model and esophageal cancer PDX model.
[0477] Materials and Methods
[0478] 12 PDX models of gastric cancer and 4 PDX models of esophageal cancer were selected for efficacy study. Mice bearing patient-derived xenografts (PDX) were randomly assigned to 2 different study groups according to their tumor volume. The average tumor volume at randomization was 100-200mm 3 . On Day 1, randomization was performed based on the "Matched distribution" randomization method (StudyDirector™ software). Mice were administered vehicle or compound A15 for 21 days (iv, twice a week).
[0479] Tumor volume was measured in two dimensions using calipers twice a week and expressed in mm3 using the following formula: tumor volume (mm3) = 0.5a x b2 (where a and b are the long and short diameters of the tumor, respectively). Relative tumor volume (RTV) was calculated us...
example 2
[0486] This study shows that compound B4 is more dependent on Bcl-xL than on Bcl-2 to function as a dual Bcl-2 / Bcl-xL inhibitor.
[0487] ABT-737 (IUPAC name: 4-{4-[(4'-chloro-2-biphenyl)methyl]-1-piperazinyl}-N-[(4-{[(2R)-4- (Dimethylamino)-1-(phenylsulfanyl)-2-butyl]amino}-3-nitrophenyl)sulfonyl]benzamide) was developed by Abbott Laboratories (now One of the first BH3 mimics developed by Abbvie. It acts as a dual BCl-2 / Bcl-xL inhibitor and promotes tumor cell apoptosis. This study compared the binding of Bcl-2 and BCl-xL between compound B4 or ABT-737.
[0488] The diffuse large B-cell lymphoma line Toledo and the acute lymphoblastic leukemia line RS4;11 were chosen for this study. Cells were treated with Compound B4 or ABT-737 at the indicated concentrations (0.025uM, 0.04uM and 0.06uM, respectively) for 24 hours and harvested for complex analysis. Both Bcl-2:BIM and Bcl-xL:BIM complexes were analyzed using the MSD advanced ELISA method.
[0489] The results show that ...
example 3
[0492] This study shows the antitumor activity of compound A15 in ASCL-1-high and Noxa-high SCLC PDX models.
[0493] SCLC is a heterogeneous disease with an extremely high mutation rate but lacks identified driver oncogenes for molecularly targeted therapies. It is currently treated in the clinic as a single disease entity. Recent studies have improved our understanding of SCLC and characterized distinct subtypes based on mutually exclusive expression of ASCL1, NEUROD1, POU2F3, or YAP1 (Rudin et al., 2019). SCLC expressing ASCL1 is the most common subtype, accounting for 70% of cases.
[0494] Noxa expression levels were obtained from 58 commercially available PDX models of SCLC (PDX models available from Crownbio). The Noxa expression levels of these 58 PDX models have been determined by RNA-sequencing and plotted in Figure 5A , where each point represents a PDX model. Based on RNA-sequencing data, Noxa expression levels ranged from below 2 to above 6 (expressed by Log2...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com